These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8706243)

  • 1. Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
    Gudas JM; Nguyen H; Li T; Sadzewicz L; Robey R; Wosikowski K; Cowan KH
    Carcinogenesis; 1996 Jul; 17(7):1417-27. PubMed ID: 8706243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells.
    Bae I; Fan S; Bhatia K; Kohn KW; Fornace AJ; O'Connor PM
    Cancer Res; 1995 Jun; 55(11):2387-93. PubMed ID: 7757991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
    Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
    Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultraviolet radiation down-regulates expression of the cell-cycle inhibitor p21WAF1/CIP1 in human cancer cells independently of p53.
    Wang JA; Fan S; Yuan RQ; Ma YX; Meng Q; Goldberg ID; Rosen EM
    Int J Radiat Biol; 1999 Mar; 75(3):301-16. PubMed ID: 10203181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
    Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
    Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines.
    Bae I; Smith ML; Sheikh MS; Zhan Q; Scudiero DA; Friend SH; O'Connor PM; Fornace AJ
    Cancer Res; 1996 Feb; 56(4):840-7. PubMed ID: 8631022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [WAF1/CIP1/p21 gene in wild type p53 and mutant p53 human breast cancer cell lines in relation to its cytobiological features].
    Jiang M; Shao Z; Wu J
    Zhonghua Zhong Liu Za Zhi; 1998 May; 20(3):181-4. PubMed ID: 10921001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma.
    Suzuki A; Toi M; Yamamoto Y; Saji S; Muta M; Tominaga T
    Jpn J Cancer Res; 1998 Feb; 89(2):221-7. PubMed ID: 9548451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
    Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
    Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
    O'Connor PM; Jackman J; Bae I; Myers TG; Fan S; Mutoh M; Scudiero DA; Monks A; Sausville EA; Weinstein JN; Friend S; Fornace AJ; Kohn KW
    Cancer Res; 1997 Oct; 57(19):4285-300. PubMed ID: 9331090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function.
    Cai Z; Capoulade C; Moyret-Lalle C; Amor-Gueret M; Feunteun J; Larsen AK; Paillerets BB; Chouaib S
    Oncogene; 1997 Dec; 15(23):2817-26. PubMed ID: 9419972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p21waf1/Cip1, MDM2 and p53 in vivo: analysis of cytological preparations.
    Dowell SP; McGoogan E; Picksley SM; el-Deiry WS; Vogelstein B; Hall PA
    Cytopathology; 1996 Oct; 7(5):340-51. PubMed ID: 8911758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p21(Waf1/Cip1) expression and the p53/MDM2 feedback loop in gastric carcinogenesis.
    Craanen ME; Blok P; Offerhaus GJ; Meijer GA; Dekker W; Kuipers EJ; Meuwissen SG
    J Pathol; 1999 Dec; 189(4):481-6. PubMed ID: 10629547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diminished capacity for p53 in mediating a radiation-induced G1 arrest in established human tumor cell lines.
    Li CY; Nagasawa H; Dahlberg WK; Little JB
    Oncogene; 1995 Nov; 11(9):1885-92. PubMed ID: 7478618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
    Keshelava N; Zuo JJ; Chen P; Waidyaratne SN; Luna MC; Gomer CJ; Triche TJ; Reynolds CP
    Cancer Res; 2001 Aug; 61(16):6185-93. PubMed ID: 11507071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
    Deptala A; Li X; Bedner E; Cheng W; Traganos F; Darzynkiewicz Z
    Int J Oncol; 1999 Nov; 15(5):861-71. PubMed ID: 10536167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.